18.01.2017 • NewsElaine BurridgeGivaudanflavor

Givaudan Acquires Activ International

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

As part of an ongoing strategy to expand its product portfolio and invest in high-growth markets, Swiss flavors and fragrances company Givaudan has added local firm Activ International to the group. Financial terms of the transaction were not disclosed.

With headquarters in Bienne, Switzerland, and sites in Paris, France; Somerset, New Jersey, USA; Melaka, Malaysia; and Arequipa, Peru, Activ employs 170 people around the world to provide a range of natural and organic flavor products.

Mauricio Graber, president of Givaudan’s Flavor Division said Activ’s portfolio further enables the Swiss group to strengthen its extensive natural flavor offerings and supply customers with complete and competitive natural solutions.

Activ’s business would have accounted for incremental sales amounting to approximately 40 million Swiss francs in Givaudan’s 2016 results on a proforma basis. Givaudan posted sales of 4.4 billion Swiss francs in 2015.

The Vernier-headquartered company said it will fund the acquisition from existing resources. Last July, Givaudan paid $340 million to buy US-based Spicetec Flavors & Seasonings from ConAgra Foods.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.